Woodford Investment Management Has A Lot Riding On These 5 Stocks
Woodford Investment Management recently filed its Form 13F with the U.S. Securities and Exchange Commission (SEC) for the reporting period of September 30.
Abbvie Inc. (ABBV)
Market is closed
News
- First
- << Previous
- 461 - 470
- Next >>
A Look at Larry Robbins' Take on the Pharma Industry and Four Picks He Is Bullish On
Larry Robbins of Glenview Capital is one of the most widely-watched investors on Wall Street.
Why Are These Four Stocks on the Move on Friday?
With the stock market ending the week on a positive note, boosted by strong earnings reported by tech giants, a number of stocks are trending amid large trading volume on the back of various news.
AbbVie, Biogen, Gilead: Smart Money Got Burned Betting on Biotech in Q3
When it rains, it pours, and for big pharma, it certainly poured in the third quarter. With the third quarter over, let's take a closer look at the fundamentals of hedge fund hotels Pfizer Inc.
These Stocks Were Upgraded This Morning And Hedge Funds Couldn't Agree More
Analysts have been busy over the weekend, as a slew of stocks have received upgrades this morning, including one company which was on the receiving end of not one, but two such bullish calls.
Here's What Excited Hedge Funds Have To Say About AbbVie Inc (ABBV)
The $98.24 billion biopharmaceutical company AbbVie Inc (NYSE:ABBV) has sparked the attention of quite a few hedge funds according to the data we compiled from the last round of 13F filings.
Billionaire Larry Robbins Has Healthy Stakes In Health Stocks
Glenview Capital, led by Larry Robbins, has recently published its 13F filing with the SEC, disclosing an equity portfolio worth $25.25 billion.
Hedge Funds Are Pouring Money Into These Stocks
With the data from the latest round of 13F filings now gathered and processed, we’ve identified five stocks that received a large influx of cash in the second quarter from the hedge funds we track.
Synageva Biopharma Corp (GEVA) Acquisition Helps Baker Bros. Advisors Top All Others In Q2 Returns
With the rapid pace of M&A happening in the biotechnology sector, Julian Baker and Felix Baker's Baker Bros. Advisors is making a habit of hitting home runs in 2015.
Deerfield Management Bets Big On Company It Polished Ahead Of IPO, Nivalis Therapeutics Inc (NVLS)
Following the initial public offering of Nivalis Therapeutics Inc (NASDAQ:NVLS) today, James E.
- First
- << Previous
- 461 - 470
- Next >>
Billionaire Hedge Funds
